Olatorepatide
Phase 2Peptide
RegeneronOlatorepatide is one of 2 small molecule programs targeting Overweight or Obesity. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Overweight or Obesity
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Overweight1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Olatorepatide. EMBL-EBI & Wellcome Sanger Institute.
- [4]